158 A novel, highly accurate liquid biopsy-based glycoproteomic predictor of checkpoint inhibitor treatment benefit in advanced non-small cell lung cancer
Biomarkers, Immune Monitoring and Novel Technologies
158 A novel, highly accurate liquid biopsy-based glycoproteomic predictor of checkpoint inhibitor treatment benefit in advanced non-small cell lung cancer